Published in Blood Weekly, June 26th, 1995
The principal application of this process is the selective and controlled cross-linking of purified human hemoglobin Ao by oxidized, ring-opened sugars. The technology applies to the production of Hemolink, Hemosol's first hemoglobin-based oxygen carrier. Hemolink is currently in Phase I clinical trials at L.A.B. Pharmacologic Research International Inc. in Montreal, Quebec, Canada.
The invention described in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.